BIOCRYST PHARMACEUTICALS INC - FORM 10-K - EX-23 - EXHIBIT 23 - March 1, 2021

Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - BIOCRYST PHARMACEUTICALS INCex_227982.htm
EX-32.1 - EXHIBIT 32.1 - BIOCRYST PHARMACEUTICALS INCex_227981.htm
EX-31.2 - EXHIBIT 31.2 - BIOCRYST PHARMACEUTICALS INCex_227980.htm
EX-31.1 - EXHIBIT 31.1 - BIOCRYST PHARMACEUTICALS INCex_227979.htm
EX-21 - EXHIBIT 21 - BIOCRYST PHARMACEUTICALS INCex_230510.htm
EX-10.92 - EXHIBIT 10.92 - BIOCRYST PHARMACEUTICALS INCex_230719.htm
EX-10.91 - EXHIBIT 10.91 - BIOCRYST PHARMACEUTICALS INCex_230714.htm
EX-10.87 - EXHIBIT 10.87 - BIOCRYST PHARMACEUTICALS INCex_230497.htm
EX-10.82 - EXHIBIT 10.82 - BIOCRYST PHARMACEUTICALS INCex_230494.htm
EX-10.36 - EXHIBIT 10.36 - BIOCRYST PHARMACEUTICALS INCex_230493.htm
EX-10.35 - EXHIBIT 10.35 - BIOCRYST PHARMACEUTICALS INCex_230492.htm
EX-10.33 - EXHIBIT 10.33 - BIOCRYST PHARMACEUTICALS INCex_230490.htm
EX-10.32 - EXHIBIT 10.32 - BIOCRYST PHARMACEUTICALS INCex_230489.htm
EX-10.29 - EXHIBIT 10.29 - BIOCRYST PHARMACEUTICALS INCex_230463.htm
EX-10.28 - EXHIBIT 10.28 - BIOCRYST PHARMACEUTICALS INCex_230471.htm
EX-10.26 - EXHIBIT 10.26 - BIOCRYST PHARMACEUTICALS INCex_230470.htm
EX-10.16 - EXHIBIT 10.16 - BIOCRYST PHARMACEUTICALS INCex_230469.htm
EX-4.1 - EXHIBIT 4.1 - BIOCRYST PHARMACEUTICALS INCex_230468.htm
10-K - FORM 10-K - BIOCRYST PHARMACEUTICALS INCbcrx20201231_10k.htm

 

Exhibit 23

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:           

 

 

●

Registration Statements (Form S-8 Nos. 333-231108, 333-239078 and 333-245024) pertaining to the BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan;

 

 

●

Registration Statements (Form S-3 Nos. 333-145638, 333-153084, 333-217859 and 333-237820) of BioCryst Pharmaceuticals, Inc.;

 

 

●

Registration Statements (Form S-8 Nos. 333-120345, 333-39484, 333-30751 and 333-136703) pertaining to the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan, as amended and restated;

 

 

●

Registration Statements (Form S-8 Nos. 333-90582 and 333-239077) pertaining to the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated;

 

 

●

Registration Statement (Form S-8 No. 333-145627) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated, and the Employment Letter Agreement dated April 2, 2007 between BioCryst Pharmaceuticals, Inc. and David McCullough;

 

 

●

Registration Statements (Form S-8 Nos. 333-176096, 333-211529, 333-218360, 333-228296, 333-231942 and 333-239076) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated;

 

 

●

Registration Statements (Form S-8 Nos. 333-152570, 333-167830, 333-187193 and 333-195869) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and the Employee Stock Purchase Plan, each as amended and restated

 

of our reports dated March 1, 2021, with respect to the consolidated financial statements of BioCryst Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of BioCryst Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of BioCryst Pharmaceuticals, Inc. for the year ended December 31, 2020.

 

/s/ Ernst & Young LLP

 

Raleigh, North Carolina

March 1, 2021

 

 

 

 

BIOCRYST PHARMACEUTICALS INC Reports